PFS Partners’s Inovio Pharmaceuticals INO Stock Holding History

PFS Partners’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-38	Closed	-$2.25K	–	357
2021 Q4	$2.25K	Buy	+38	New	+$3.04K	﹤0.01%	303

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFS Partners's INO Position: Q1 2022 in Review

PFS Partners sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 38 shares — an estimated $2.25K sold.

PFS Partners first reported a position in INO in Q4 2021 and held it in 1 quarter. The position peaked at $2.25K in Q4 2021. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

PFS Partners reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
PFS Partners sold 38 Inovio Pharmaceuticals shares in Q1 2022, an estimated $2.25K.
PFS Partners first reported a position in Inovio Pharmaceuticals in Q4 2021 and held it in 1 quarter.
PFS Partners's Inovio Pharmaceuticals position peaked at $2.25K in Q4 2021.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on PFS Partners's 13F filing for Q1 2022, filed 1 Dec 2023.